Physician profile
April M Dodder
NPI 1114394053
$2,923.93
in general payments reported to CMS, 2019-2025
23 companies · $530 in 2025
The $530 reported for 2025 was more than what 87% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $305 · 2022: $482 · 2023: $837 · 2024: $771 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,948 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,947.87 |
| Education | $189.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $495.76 | 2023-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $446.89 | 2021-2025 | |
| Organon LLC | $289.89 | 2021-2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $281.80 | 2022-2025 | |
| Exeltis, USA INC. | $212.84 | 2021-2025 | Slynd |
| Mayne Pharma Commercial LLC | $181.73 | 2023-2025 | |
| Coloplast Corp | $145.27 | 2022-2025 | Altis |
| Sage Therapeutics, LLC | $131.31 | 2024-2025 | Zurzuvae |
| Avanos Medical | $117.92 | 2021-2024 | On-Q* Pump and Accessories |
| Hologic Sales and Service, LLC | $107.27 | 2021-2024 | Acessa Provu System, Fluent Fluid Management System |
| Coopersurgical, INC. | $102.05 | 2021-2023 | Paragard T 380a |
| Sumitomo Pharma America, INC. | $75.28 | 2024-2025 | Myfembree |
| Shield Therapeutics INC | $73.58 | 2024 | |
| Daiichi Sankyo INC. | $65.73 | 2021-2022 | |
| Pfizer INC. | $32.52 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $28.20 | 2025 | Quikclot |
| Idorsia Pharmaceuticals US INC | $26.76 | 2023 | Quviviq |
| Roche Diagnostics Corporation | $21.48 | 2021 | |
| Evofem Biosciences, INC. | $20.26 | 2022 | |
| Avion Pharmaceuticals | $19.70 | 2022 | |
| Therapeuticsmd, INC. | $16.78 | 2022 | |
| Supernus Pharmaceuticals, INC. | $16.70 | 2025 | Qelbree |
| Axonics, INC. | $14.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Dodder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.